After acquiring Flaskworks achieving new success in developing drugs for cancer became real in the eyes of Northwest Biotherapeutics (NWBO) that is facing steady growth in the OTC market. Through several years Northwest has been burning cash to come out with innovative drugs to fight rare types of cancer.
For the last six months, the stock surged steeply thrice; in the last week of May, in the first week of September, and in mid-September. There is no downtrend seen at all for that period. NWBO seems to grow further by having a strong foundation from the gaining pattern in the price chart.
Very soon, many biotech fans will likely buy NWBO shares imitating the situation of Relief Therapeutics (RLFTF) that is trending in searches and investing forums due to its candidate for the COVID-19 vaccine. Getting a couple of hundred NWBO shares might open an experimental area for investing in OTC stocks which allow many traders to win 10 times bigger returns.